Artelo Biosciences/$ARTL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Artelo Biosciences
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
- Ticker
- $ARTL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Solana Beach, United States
- Website
- artelobio.com
ARTL Metrics
BasicAdvanced
$2M
-
-$102.42
-0.08
-
Price and volume
Market cap
$2M
Beta
-0.08
52-week high
$15.73
52-week low
$3.45
Financial strength
Current ratio
3.004
Quick ratio
2.885
Long term debt to equity
0.001
Total debt to equity
0.01
Interest coverage (TTM)
-33.04%
Profitability
Management effectiveness
Return on assets (TTM)
-127.92%
Return on equity (TTM)
-705.71%
Valuation
Price to book
0.34
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-0.036
Free cash flow yield (TTM)
-2,774.69%
Free cash flow per share (TTM)
-102.108
Growth
Earnings per share change (TTM)
-79.99%
3-year earnings per share growth (CAGR)
-42.43%
ARTL Financial Performance
Revenues and expenses
ARTL Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.